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Abstract: We carried out a protein and genetic investigation of the factor H gene mutations 
within two families presenting with a diagnostic suspicion of atypical hemolytic uremic syndrome 
(aHUS). The results within the patients of the first family revealed a factor H-deficiency. Direct 
sequencing allowed the detection of a 4-nucleotide deletion in the factor H gene. This deletion 
was found as the homozygote form in the proband and as the heterozygote form in the parents. 
Protein and functional analyses of the complement system were normal in all members of the 
second family. However, the molecular investigation for the father showed the presence of an 
amino acid substitution in the FH gene. Unfortunately, his two affected children died without 
being investigated for mutations. The functional consequences of these abnormal proteins are 
still to be demonstrated.
Keywords: atypical hemolytic uremic syndrome, complement, alternative pathway, factor H, 
deletion, nucleotide substitution
Introduction
Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy characterized by 
hemolytic anemia and thrombocytopenia often complicated by acute renal failure in 
children.1 Both typical or diarrhea-associated HUS form is associated with infection 
by Escherichia coli and has a good prognosis.2 A second less common from, termed 
atypical, nondiarrhea-associated HUS (aHUS) is a heterogeneous recurrent disorder 
which displays high mortality and morbidity.3 This form can occur at any age with 
familial and sporadic cases. HUS is defined as familial when at least two members 
of the same family are affected by the disease at least 6 months apart. Familial aHUS 
exists in patterns of both autosomal dominant and recessive inheritance.4 Triggers for 
the sporadic form include infection with human immunodeficiency virus, cancer, use 
of immunotherapeutic agents, diseases and pregnancy.3 However, approximately 50% 
of sporadic cases appear to be idiopathic.4
It has recently been shown that aHUS is associated with mutations in the complement 
regulatory protein factor H (FH).5–8 The FH gene is located on chromosome 1q32 within 
a cluster of genes encoding the regulatory complement components of the activation of 
C3.9 These genes encode proteins, which consist of multiple homologous modules called 
“complement control protein modules” (CCPs), previously known as short consensus 
repeats (SCRs).10 Each SCR is 60 amino acids in length and has four cysteine residues 
which form two disulphide bridges: Cys1–Cys3 and Cys2–Cys4. These disulfide 
bridges are important in maintaining the characteristic structure of the SCR module.11International Journal of Nephrology and Renovascular Disease 2010:3 86
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The 155Kd fluid phase glycoprotein FH, is composed 
of 20 SCRs each encoded by a single exon, with the 
  exception of the second SCR encoded by exon 2a and 2b.12 
It regulates the alternative pathway (AP) by competing 
with factor B for binding to C3b and acting as a cofactor 
for factor I, leading to proteolytic inactivation of C3b.13,14 
Factor H can also interact with polyanionic molecules (sialic 
acids or glycosaminoglycans) on certain cellular surfaces 
  conferring to them a resistance to damage as a consequence 
of complement activation through the AP.15
In order to identify potential FH mutations predisposing 
to aHUS, we performed a protein and genetic analysis of 
FH within two Tunisian families presenting a diagnostic 
suspicion of aHUS.
Materials and methods
Patients
Patients were recruited from the Pediatric department of 
Mahdia Hospital in Central Tunisia. 
Family A pedigrees and case histories  
are shown in Figure 1
The family exhibited a high grade of consanguinity.
Patient I-4
A 25-day-old Tunisian boy with a family history of the death of 
a brother (I-2) and four cousins (I-5, I-6, I-7 and I-8) (Table 1) 
by HUS confirmed by postmortem renal biopsy presented 
initially with pallor, fever, refusal to suckle, and vomiting, 
but without any notion of diarrhea. A clinical examination 
found tachypnea, lethargy, a temperature of 39.6°C, and 
hypertension (blood pressure was 120/80 mmHg), with 
evidence of fluid overload. Initial investigations performed 
were as follows: a severe anemia with hemoglobin level 
of 5.9 g/dL, platelet count of 140000/mm3, schistocytosis 
at 16%, hematuria and proteinuria (3.3 g/day). The blood 
level of urea was 16 mM/L and the glomerular filtration rate, 
estimated using the Cockcroft–Gault equation for creatinine 
  clearance (eGFR) was 41 mL/min/1.73 m2. A diagnosis of 
atypical hemolytic uremia (aHUS) was established. A renal 
biopsy was performed and disclosed a pattern of throm-
botic microangiopathy predominantly in the glomeruli 
with few vascular lesions. At this stage, he was transfused 
by leukocyte-depleted red blood cells. Administration of 
2000 mL fresh frozen plasma (FFP) was undertaken for seven 
consecutive days associated with intravenous furosemide at 
maximal dose (2 mg/kg/day) and antihypertensive therapy 
was achieved with intravenous nicardipine (1 mg/kg/day). 
An adequate control was gained 20 days later using the same 
oral drugs with a normal renal function. A relapse occurred 
6 months later, with acute renal failure that required peri-
toneal dialysis and fresh frozen plasma administration for 
10 days. The patient regained independent renal function. 
At the time of writing, 2 years after onset, his renal function 
has remained normal with twice-monthly plasma infusions 
and no relapse of hemolysis has occurred.
Patient I-2
This 5-month-old Tunisian boy was referred for anemia 
(hemoglobin level of 4.9 g/dL), thrombocytopenia (platelet 
count of 100000/mm3) and acute renal failure (creatinine 
clearance was 41 mL/min/1.73 m2), leading to death at day 
2 despite standard therapy and plasma infusions. Analysis 
of post-mortem renal biopsy material revealed ischemic 
glomeruli and fibrotic lesions in arteria and interstitium 
without deposition of C3.
Patients I-5, I-6, I-7, and I-8
These children, who were brothers and first cousins of 
patients I-2 and I-4, were referred to pediatric center for 
rapidly progressive renal failure, hypertension since the age 
of 52, 15, and 25 days, respectively (Table 1). Although, 
combining diuretics and angiotensin-converting enzyme 
inhibitors treatment, the clinical progression was critical 
with the rapid death of patients I-6, I-7, and I-8 a few days 
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Figure 1 Pedigrees of family 1 and 2: Solid circles and squares represent respectively 
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Table 1 Case histories of families A and B
Family Subject Status/Disease Onset of  
disease
Clinical features Treatments Disease  
outcome
A I-1 Unaffected – – – –
A I-2 Affected/HUS 5 months Severe hypertension  
dyspnea, anemia  
Acute pulmonary edema
Plasma infusions  
Antihypertensives
Death 2 days  
after onset
A I-3 Unaffected – – – –
A I-4 Affected/HUS 25 days Severe hypertension  
edema, anemia  
Renal failure refusal to  
suckle, proteinuria,  
hematuria
Plasma infusions  
Peritoneal dialysis  
Antihypertensive  
agents
Relapse 6 months 
after diagnosis  
Currently, normal 
renal function
A I-5 Affected/HUS 52 days Renal failure  
Severe hypertension  
Anemia heart failure  
proteinuria, hematuria
Plasma infusions  
Antihypertensive  
agents
One recurrence  
15 days after  
diagnosis  
Death 4 months 
after diagnosis
A I-6 Affected/HUS 15 days Renal failure  
Severe hypertension  
Anemia proteinuria,  
hematuria
Plasma infusions  
Antihypertensive  
agents
Death 3 days  
after diagnosis
A I-7 Affected/HUS 25 days Renal failure  
Severe hypertension  
pneumonia  
Anemia proteinuria, hematuria
Plasma infusions  
Antihypertensive  
agents
Death 12 days  
after diagnosis
A I-8 Affected/HUS 25 days Renal failure  
Severe hypertension  
Vomiting  
Anemia  
proteinuria, hematuria
Plasma infusions  
Antihypertensive  
agents
Death 12 days  
after diagnosis
A I-9  
I-10
Unaffected – – – –
A II-6  
II-7  
II-8
Unaffected – – – –
A II-12  
II-13
Unaffected – – – –
A III-1  
III-5  
III-7
Unaffected – – – –
B I-1 Affected/HUS 6 months Renal failure  
Severe hypertension  
heart failure  
proteinuria, hematuria
Plasma infusions  
Antihypertensive  
agents
Death 24 hours  
after diagnosis
B I-2 Affected/HUS 18 months Renal failure  
Severe hypertension  
Vomiting  
Anemia  
proteinuria, hematuria
Plasma infusions  
Antihypertensive  
agents
Death 12 hours  
after diagnosis
B I-3  
I-4  
I-5  
I-6
Unaffected – – – –
B II-1  
II-2
Unaffected – – – –International Journal of Nephrology and Renovascular Disease 2010:3 88
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after admission and before the use of peritoneal dialysis. At 
the acute phase, patient I-5 had also received a transfusion 
of packed red blood cells, plasma-exchanges and intravenous 
antihypertensive therapy. He regained independent renal 
function (creatinine clearance: 50 mL/min/1.73 m2) ten days 
after the initial episode. However, a recurrence of HUS 5 days 
later required weekly administration of FFP for a period of 
2 months. Following acute otitis at the age 4 months, the child 
was referred for another episode of HUS. Despite the standard 
therapy, he died 48 hours after hospitalization. Analysis of 
post-mortem renal biopsy specimens revealed the presence 
of severe thrombotic microangiopathy lesions.
Family B pedigrees and case histories
This second family had the same geographic origin as the 
first family. No complement exploration could be performed 
for patient’s I-1 and I-2. Only five healthy members were 
serologically investigated and genotyped (Figure 1).
Patient I-1
A 6-month-old Tunisian boy, born to high grade-consanguineous 
parents was referred with a history of fever and gross 
hematuria without diarrhea prodromal. The patient exhibited 
anemia with hemoglobin level of 7.9 g/dL, thrombocytopenia 
(platelet count of 140000/mm3), renal insufficiency 
(creatinine clearance: 38 mL/min/1.73 m2) and hypertension 
(120/80 mmHg). While receiving diuretics and intravenous 
antihypertensive therapy, the children died abruptly and the 
postmortem renal biopsy showed  ischemic shrinkage of the 
capillaries with lesions of thrombotic microangiopathy.
Patient I-2
This Tunisian girl was presented with atypical HUS at the 
age of 18 months with rapidly critical clinical progression 
and death just a few hours after admission and before the use 
of peritoneal dialysis. Analysis of postmortem renal biopsy 
material revealed the same thrombotic microangiopathy 
lesions as her brother I-1 (Table 1).
Controls
One hundred fifty healthy controls matched for sex, ethnic, 
and geographic origin were also studied. Medical examination 
and a questionnaire were performed for all controls. Exclusion 
criteria were HUS in the donor or in a first-degree relative.
Patients and controls received detailed information on 
the purpose of the study. It was approved by the local eth-
ics committee and a priori consent was obtained from all 
subjects.
Materials
Complement assays
Measurement of total hemolytic complement (CH50) and 
alternative pathway (AP50) activities in EDTA samples 
were determined using the method of Mayer.16 Plasma 
  concentrations of C4, C3, and Factor B (FB) antigens were 
measured by nephelometry (MininephTM; The Binding Site, 
Birmingham, UK). Plasma levels of the third and/or fourth 
complement component below the lower limit of normal 
ranges (Table 2), defined as mean ± 2 standard deviations 
(SD) were taken to indicate hypocomplementemia.
Serum samples were used to quantify Factor H antigen 
concentration by enzyme-linked immunosorbent assay 
(ELISA) assay, described previously by Dragon-Durey.17 
Normal ranges were 100% ± 30% as calculated by the results 
from 100 healthy individual donors.
Genomic FH DNA sequencing
Genomic DNA was amplified by means of polymerase chain 
reaction (PCR) using nucleotides flanking each exon. For 
all patients, all 22 FH exons were sequenced and analyzed. 
The number of nucleotide or codon referenced is indicated 
according to Warwicker and colleagues.5
Prediction of effects of amino acid substitutions
The PolyPhen server (see http://www.bork.embl-heidelberg. 
de/PolyPhen/) was used to predict the likely impact of 
non-synonymous amino acid substitutions or deletions, 
observed in patients and controls.
Results
Complement component assessment
Plasma complement profiles at the time of diagnosis are 
listed in Table 2. Results of complement investigation were 
confirmed at least twice.
Family A
Patient I-4 exhibited severe complement consumption 
through the alternative pathway, as indicated by very low 
plasma levels of CH50, AP50, C3, and FB. This patient 
presented a plasma concentration of FH protein below 1%. 
These results are in concordance with homozygous FH 
deficiency.
Plasma complement profile measurement showed mildly 
decreased CH50 and AP50, low C3 and FB plasma levels in 
patients’ I-1, I-3, I-10, II-6, II-7, II-12, II-13, III-5, and III-7. 
Antigenic plasma levels of FH were between 35% and 50% 
of normal values, suggesting heterozygous FH deficiency.International Journal of Nephrology and Renovascular Disease 2010:3 89
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Family B
In all the investigated healthy members a FH antigenic level 
and C3 and FB plasma levels were normal.
Characterization of the genetic defect
Family A
Genomic sequencing showed a four-bp TAGA or ATAG 
deletion in SCR 20 of factor H, between nucleotides of 3767 
and 3770, as a homozygous state in the patient (I-4) and a 
heterozygous state in the parents; and all family members 
carried heterozygous FH deficiency (Figure 2). This mutation 
leads to the loss of the normal stop codon (TAG) inducing 
a frame shift in factor H coding sequence. The predicted 
protein sequence shows 37 additional amino acid changes 
induced by this deletion.
Family B
A nucleotide substitution G to C at position 3617 resulting 
in an arginine/threonine heterozygous nonsense mutation 
at 1182 codon from SCR 20 was detected in the father 
(II-1). The predictive translation shows that this nucleotide 
substitution induced structural change in the hypervariable 
loop of SCR-20 between strands β2 and β3. However, the 
healthy mother (II-2) and brothers (I-3, I-4, I-5) do not exhibit 
the same substitution.
Controls
Both molecular deletion and nucleotide substitution were 
not found in 150 Tunisian healthy controls or reported in 
other control populations and thus are unlikely to represent 
allelic variants.
Discussion
FH deficiencies have been reported in both homozygous 
and heterozygous forms associated with aHUS and other 
kidney diseases such as type II or III membranoproliferative 
  glomerulonephritis.8 Genetic studies have found several 
  missense mutations between SCR16 and SCR20 suggesting a 
particular role of the C-terminal domains of the FH protein.18–22 
This region is important for binding to C3b and sialic acid 
  residues on to cell surfaces. Mutations in this region, therefore, 
impair the ability of factor H to protect against complement-
mediated host cell damage which may cause the vascular 
injury observed in HUS.18 In a complete FH deficient proband 
we have identified a molecular abnormality consisting of 
a 4-bp TAGA or ATAG deletion leading to a normal stop 
codon loss and inducing a longer protein with 37 additional 
amino acids. According to the family tree, whoever has a 
high degree of consanguinity, this deletion is transmitted in 
an autosomal recessive form. The conformational change 
could explain the production of a macromolecule unable to 
be secreted or quickly hydrolyzed. We speculate that this 
hypothesis explains the total deficiency of the H protein in 
our present case. It also could explain the partial deficiency 
of the FH antigen level in heterozygous members. Protein 
crystallography and immunohistochemical analyses are 
necessary to clarify the molecular mutant protein synthesis, 
as well as its cellular secretion.
Table 2 Results of complement investigations
Family Subject CH50  
25–61 U/ml
C3 121 ± 
36 mg/100 ml
C4 26 ± 
12 mg/100 ml
AP50 100% Factor H  
100% ± 30%
Factor B 20 ± 
11 mg/100 ml
A I-1 27 90 26.4 52 50 10
A I-3 29.4 85 22.3 50 50 8.5
A I-4 10 48.3 15.7 5 1 8
A I-9 27 100.1 26 80 90 27
A I-10 24 75.3 14.4 35 35 11
A II-6 27 85.5 87.7 50 50 8
A II-7 26.3 82 24 50 35 6.8
A II-8 28.1 131.9 11.7 100 100 27
A II-12 15.3 85.8 34.1 50 30 10
A II-13 28.5 91 34.1 35 30 10
A III-1 26.6 127.9 24.6 100 95 27
A III-5 10 86.9 34.1 50 35 8
A III-7 14.2 85.1 31.6 50 50 8
B I-3 25 128.1 24.5 80 100 18
B I-4 25 128.5 11.8 50 100 15
B I-5 25 121.4 16.9 52 85 18
B II-1 25 144.6 56.2 50 100 18
B II-2 25 129.3 38.9 100 95 18International Journal of Nephrology and Renovascular Disease 2010:3 90
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This genetic abnormality has been previously described 
by Sellier-Leclerc23 and Sethi24 who report FH antigenic level 
at 4% and 10% respectively. Sethi and colleagues24 have 
not detected by Western blot the abnormal protein in 
serum, suggesting an impairment of the secretion of this 
FH protein would be retained in the cytoplasm. Also, 
Neumann7 described a deletion of four nucleotides AGAA 
at a position 3768 of the nucleotide sequence inducing 
the same frameshift consequences. Several therapies, 
such as plasma administration and plasma exchanges 
were used in patients with aHUS in order to supplement 
  factor H deficiencies.25 However, a combined liver-kidney 
  transplantation was required in case of the progression 
to end-stage renal disease.26 In all the cases described by 
Sellier-Leclerc,23 Sethi24 and Neumann,7 patients exhibited 
the evolution chronic kidney disease and awaited a renal 
transplantation.
To date, while the FH antigenic level was below than 
1%, the renal function of our present case remains normal 
under regularly plasma infusions. This clinical course is 
also extremely different from that observed in his brother 
and the first cousins both of whom died abruptly, despite 
standard therapy. The results of our data suggests that the 
genetic predisposition to complement FH dysregulation was 
A)
B)
C)
Figure 2 DNA sequencing for a section of factor H SCR20 in family A.
Notes: A) Wild type chromatogram, B) Chromatogram of I–4 patient: After the nucleotides AAAAAGA, there is a deletion of 4 nucleotides TAGA (3767_3771delTAGA), 
C) Chromatogram of a heterozygous patient with superposed peaks from the wild-type and mutant alleles.International Journal of Nephrology and Renovascular Disease 2010:3 91
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perhaps due to a trigger event such as infection or a second 
  susceptibility factor which has not yet been identified.
Other genetic abnormalities involved in the impairment 
of intrachain disulfide bonds leading to the change of the 
secondary structure of the protein were also described.17 
Similar mutations involving a cysteine in SCR 9 and 16 
were previously reported by Ault27 and Schmidt28 and it has 
been demonstrated that the 150-kD protein was retained in 
the intracellular fraction. In our data, such mutations were 
not detected.
Several studies have shown that many patients had a 
functionally significant mutation in the absence of alternative 
pathway consumption.21 Consequently, and despite the 
  normal C3 and factor H levels, we processed to CFH 
mutation screening in the family B. A single heterozygous 
base pair substitution at 1182 codon involving an arginine 
(Arg) that was changed to a threonine (Thr) was found in 
the father. Nuclear magnetic resonance and chemical shift 
mapping indicated that Arg1182 is one of the eight residues 
involved in heparin binding.29,30 The majority of mutations 
that occur within, or close proximity to, this loop show a 
type II phenotype (in which serum levels of factor H are 
normal).31,32
In our data, we report two genetically different abnor-
malities in aHUS consanguineous families. The mechanisms 
by which these factor H mutations lead to this disease are 
not fully understood. Further biochemical and functional 
studies will provide deeper insights into the pathogenesis 
of aHUS.
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